Calidi Therapeutics Designed New Oncolytic Virus Therapy
A new systemic therapy for advanced cancers is moving toward human trials in the United States.
Updated on Oct. 2, 2026 in Cancer
Live Poll
Should medical research prioritize systemic drug delivery over site-specific injection methods for cancer patients?
Calidi Therapeutics is preparing to submit an investigational new drug application for CLD-401, a novel oncolytic virus candidate. The therapy is designed to treat metastatic cancers, including melanoma and non-small cell lung cancer.
Why it matters
Systemic delivery addresses the challenge of treating metastatic cancer sites that are often difficult to access via direct injection. This approach removes the need for specialized surgical expertise required for traditional intratumoral therapy.
The therapy involves an engineered virus with three replication-essential genes deleted to restrict growth. Preliminary data indicates the virus only replicates in hypermetabolic tumor cells, though its safety in human trials has yet to be determined.
The players
Calidi Therapeutics
A biotechnology company focused on developing oncolytic virus therapies to treat various solid tumor cancers.
Eric Poma
The current CEO of Calidi Therapeutics who has led the company since April 2025.
The details
CLD-401 is engineered to express the protein CD55 and an IL-15 super agonist to help stimulate an immune response against the tumor. By coating the virus in a human membrane, the therapy aims to evade detection by the patient's immune system. The virus is specifically programmed to replicate only in cells that exhibit hypermetabolic activity and high growth factor levels, effectively targeting tumor cells while sparing healthy tissue.
Timeline
Eric Poma became CEO of Calidi Therapeutics in April 2025.
Health Landscape
Oncolytic virus research aims to overcome the accessibility issues associated with traditional intratumoral injections. This candidacy reflects a broader trend of engineering systemic viruses to target tumors while minimizing off-target immune reactions.
As this is currently an investigational candidate, there is no immediate change to existing treatment plans. Patients interested in how emerging clinical trials might align with their specific diagnosis should discuss current options and upcoming research protocols with their oncologist.
The takeaway
Systemic oncolytic viruses are being developed to treat metastatic cancers that are difficult to reach with surgery or direct injections. Keep this therapeutic strategy in mind when discussing trial eligibility or new treatment research with your physician.
Further reading
For more on the latest research in oncology treatments, visit our Cancer section.
Source note: This article includes information reported by Clinicalleader.
Live Poll
Should medical research prioritize systemic drug delivery over site-specific injection methods for cancer patients?
